RT Journal Article
SR Electronic
T1 Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 653
OP 658
DO 10.1136/jclinpath-2017-204828
VO 71
IS 7
A1 Keegan, Alissa
A1 Charest, Karry
A1 Schmidt, Ryan
A1 Briggs, Debra
A1 Deangelo, Daniel J
A1 Li, Betty
A1 Morgan, Elizabeth A
A1 Pozdnyakova, Olga
YR 2018
UL http://jcp.bmj.com/content/71/7/653.abstract
AB Objectives To evaluate peripheral blood (PB) for minimal residual disease (MRD) assessment in adults with acute lymphoblastic leukaemia (ALL).Methods We analysed 76 matched bone marrow (BM) aspirate and PB specimens independently for the presence of ALL MRD by six-colour flow cytometry (FC).Results The overall rate of BM MRD-positivity was 24% (18/76) and PB was also MRD-positive in 22% (4/18) of BM-positive cases. We identified two cases with evidence of leukaemic cells in PB at the time of the extramedullary relapse that were interpreted as MRD-negative in BM.Conclusions The use of PB MRD as a non-invasive method for monitoring of systemic relapse may have added clinical and diagnostic value in patients with high risk of extramedullary disease.